Akebia Therapeutics (AKBA) Non Operating Income (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Non Operating Income data on file, last reported at -$4.7 million in Q1 2026.

• On a quarterly basis, Non Operating Income rose 39.63% year-over-year to -$4.7 million in Q1 2026; TTM through Mar 2026 was -$21.1 million, a 10.05% increase from a year earlier, with the FY2025 full-year figure at -$24.2 million, down 32.96% from the prior year.
• Non Operating Income for Q1 2026 stood at -$4.7 million, up from -$4.8 million in the prior quarter.
• Over the last five years, Non Operating Income for AKBA reached as high as -$1.4 million in Q3 2023 and fell as low as -$7.8 million in Q1 2025.
• Historically, Non Operating Income has averaged -$4.0 million across 5 years, with a median of -$4.7 million in 2026.
• Across the five-year window, Non Operating Income surged 69.16% in 2023 and tumbled 384.98% in 2024, its largest moves.
• Year by year, Non Operating Income stood at -$1.6 million in 2022, then gained by 13.33% to -$1.4 million in 2023, then slumped by 384.98% to -$6.9 million in 2024, then grew by 29.81% to -$4.8 million in 2025, then rose by 2.82% to -$4.7 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were -$4.7 million in Q1 2026, -$4.8 million in Q4 2025, and -$4.7 million in Q3 2025.